Ochre Bio
Signal active
Organization
Contact Information
Overview
Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.
Ochre Bio is within the heart of Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
About
Industries
Biotechnology, Health Care, Biopharma, Therapeutics
Founded
2019
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
Ochre Bio headquartered in Europe, operates in the Biotechnology, Health Care, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $2.5B in funding across 64 round(s). With a team of 11-50 employees, Ochre Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Ochre Bio, raised $30.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
11
Lead Investors
0
Total Funding Amount
$39.8M
Details
4
Ochre Bio has raised a total of $39.8M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Seed | 150.0K | ||
| 2021 | Seed | 9.6M | ||
| 2021 | Early Stage Venture | |||
| 2022 | Early Stage Venture | 30.0M |
Investors
Ochre Bio is funded by 35 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| BACKED VC | - | FUNDING ROUND - BACKED VC | 30.0M |
| Selvedge Venture | - | FUNDING ROUND - Selvedge Venture | 30.0M |
| Ochre Bio | - | FUNDING ROUND - Ochre Bio | 30.0M |
| Martin Chavez | - | FUNDING ROUND - Martin Chavez | 30.0M |
Recent Activity
There is no recent news or activity for this profile.